• Explore /
  • Poster
  • / Impact of age on efficacy and safety of daratumumab in combination with lenalidomide and dexamethasone (D-Rd) in patients (pts) with transplant-ineligible newly diagnosed multiple myeloma (NDMM): MAIA.

Impact of age on efficacy and safety of daratumumab in combination with lenalidomide and dexamethasone (D-Rd) in patients (pts) with transplant-ineligible newly diagnosed multiple myeloma (NDMM): MAIA.

Abstract Poster

Authors

Saad Usmani

Saad Zafar Usmani

Levine Cancer Institute/Atrium Health, Charlotte, NC

Saad Zafar Usmani , Thierry Facon , Shaji Kumar , Torben Plesner , Philippe Moreau , Supratik Basu , Hareth Nahi , Margaret Macro , Hang Quach , Aurore Perrot , Chris Venner , Katja Weisel , Noopur S. Raje , Michel Attal , Xavier Leleu , Maria Krevvata , Jianping Wang , Rachel Kobos , Cyrille Hulin

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies—Plasma Cell Dyscrasia

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

NCT02252172

Citation

J Clin Oncol 37, 2019 (suppl; abstr 8035)

DOI

10.1200/JCO.2019.37.15_suppl.8035

Abstract #

8035

Poster Bd #

361

Abstract Disclosures

Similar Posters

First Author: Sebastian Grosicki

First Author: Pieter Sonneveld

First Author: Thierry Facon

First Author: Andree Kurniawan